Allergan Aesthetics’ Skinvive by Juvéderm Receives FDA Approval for the Improvement of Neck Appearance

Allergan Aesthetics, an AbbVie company, announced the U.S. Food and Drug Administration (FDA) approval of Skinvive by Juvéderm to reduce neck lines for the improvement of neck appearance in adults over the age of 21.

With this approval, Skinvive by Juvéderm is the first and only hyaluronic acid (HA) injectable indicated to reduce the appearance of neck wrinkles and help skin retain its natural moisture, leading to an improved neck appearance.

Skinvive by Juvéderm injectable gel was first FDA approved in 2023 to improve skin smoothness of the cheeks in adults over the age of 21.

Skinvive by Juvéderm reduces neck lines by helping the skin retain its natural moisture, softness, and smoothness. Treatment is minimally invasive with little to no downtime and is administered using an ultrafine needle or cannula, with a small amount of local anesthetic (lidocaine) to support patient comfort during treatment. Results last six months with optimal treatment.

“The approval of SKINVIVE by JUVÉDERM® for horizontal neck wrinkles reflects Allergan Aesthetics’ commitment to developing science-driven innovations that address meaningful unmet aesthetic needs,” said Darin Messina, Ph.D., senior vice president, aesthetics R&D, AbbVie, said in a release. “This approval expands our portfolio of lower face and neck treatment options and gives patients and aesthetic providers a first-of-its-kind treatment option for improving neck skin quality and reducing the appearance of neck lines.”

Allergan Aesthetics will provide a training program for all interested providers, successful completion of which is necessary prior to purchase of and administration of Skinvive by Juvéderm for the improvement of neck appearance. Look for the product to become commercially available later this year.

To learn more about Skinvive by Juvéderm and view important safety information, visit www.skinvive.com.